243 related articles for article (PubMed ID: 27958190)
1. ONCOLOGISTS' BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY.
Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes K; Wheeler SB
Int J Technol Assess Health Care; 2016 Jan; 32(5):355-361. PubMed ID: 27958190
[TBL] [Abstract][Full Text] [Related]
2. How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients.
Zhu X; Dent S; Paquet L; Zhang T; Tesolin D; Graham N; Aseyev O; Song X
Curr Oncol; 2021 Feb; 28(1):800-812. PubMed ID: 33557029
[TBL] [Abstract][Full Text] [Related]
3. Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay.
Zipkin R; Schaefer A; Chamberlin M; Onega T; O'Malley AJ; Moen EL
Cancer Med; 2021 Feb; 10(4):1253-1263. PubMed ID: 33455068
[TBL] [Abstract][Full Text] [Related]
4. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Carey LA; Troester MA; Wheeler SB
J Clin Oncol; 2016 Jan; 34(2):130-8. PubMed ID: 26598755
[TBL] [Abstract][Full Text] [Related]
5. Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010-2016.
Schwedhelm TM; Rees JR; Onega T; Zipkin RJ; Schaefer A; Celaya MO; Moen EL
BMC Cancer; 2020 Sep; 20(1):847. PubMed ID: 32883270
[TBL] [Abstract][Full Text] [Related]
6. Patient-Centered Communication for Discussing Oncotype DX Testing.
Roberts MC; Bryson A; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Wheeler SB
Cancer Invest; 2016 May; 34(5):205-12. PubMed ID: 27124287
[TBL] [Abstract][Full Text] [Related]
7. The effect of Oncotype DX
Rabie MA; Rankin A; Burger A; Youssef M
Ann R Coll Surg Engl; 2019 Nov; 101(8):596-601. PubMed ID: 31219316
[TBL] [Abstract][Full Text] [Related]
8. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis.
Carlson JJ; Roth JA
Breast Cancer Res Treat; 2013 Aug; 141(1):13-22. PubMed ID: 23974828
[TBL] [Abstract][Full Text] [Related]
9. The value of personalizing medicine: medical oncologists' views on gene expression profiling in breast cancer treatment.
Bombard Y; Rozmovits L; Trudeau M; Leighl NB; Deal K; Marshall DA
Oncologist; 2015 Apr; 20(4):351-6. PubMed ID: 25746345
[TBL] [Abstract][Full Text] [Related]
10. The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable.
Chin-Lenn L; De Boer RH; Segelov E; Marx GM; Hughes TM; McCarthy NJ; White SC; Foo SS; Rutovitz JJ; Della-Fiorentina S; Jennens R; Antill YC; Tsoi D; Cronk MF; Lombard JM; Kiely BE; Chirgwin JH; Gorelik A; Mann GB
Asia Pac J Clin Oncol; 2018 Dec; 14(6):410-416. PubMed ID: 30270527
[TBL] [Abstract][Full Text] [Related]
11. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort.
Ademuyiwa FO; Miller A; O'Connor T; Edge SB; Thorat MA; Sledge GW; Levine E; Badve S
Breast Cancer Res Treat; 2011 Apr; 126(3):797-802. PubMed ID: 21197567
[TBL] [Abstract][Full Text] [Related]
12. Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing.
Fallowfield L; Matthews L; May S; Jenkins V; Bloomfield D
Psychooncology; 2018 Apr; 27(4):1264-1269. PubMed ID: 29448311
[TBL] [Abstract][Full Text] [Related]
13. The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings.
Alkushi A; Omair A; Masuadi E; Alamri G; Abusanad A; Abdelhafiez N; Mohamed AE; Abulkhair O
Cureus; 2021 Feb; 13(2):e13298. PubMed ID: 33738150
[TBL] [Abstract][Full Text] [Related]
14. Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing.
Roberts MC; Weinberger M; Dusetzina SB; Dinan MA; Reeder-Hayes KE; Troester MA; Carey LA; Wheeler SB
Breast Cancer Res Treat; 2015 Aug; 153(1):191-200. PubMed ID: 26216535
[TBL] [Abstract][Full Text] [Related]
15. Benefits of introduction of Oncotype DX
Green N; Al-Allak A; Fowler C
Ann R Coll Surg Engl; 2019 Jan; 101(1):55-59. PubMed ID: 30322288
[TBL] [Abstract][Full Text] [Related]
16. Uptake of BRCA 1/2 and oncotype DX testing by medical and surgical oncologists.
Murciano-Goroff YR; McCarthy AM; Bristol MN; Groeneveld P; Domchek SM; Motanya UN; Armstrong K
Breast Cancer Res Treat; 2018 Aug; 171(1):173-180. PubMed ID: 29737473
[TBL] [Abstract][Full Text] [Related]
17. The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer.
Rizki H; Hillyar C; Abbassi O; Miles-Dua S
Cureus; 2020 Mar; 12(3):e7269. PubMed ID: 32195072
[TBL] [Abstract][Full Text] [Related]
18. Adherence Disparities and Utilization Trends of Oncotype Dx Assay: A National Cancer Database Study.
Chen S; Thacker C; Wang S; Young KA; Hoffman RL; Blansfield JA
J Surg Res; 2023 Jun; 286():65-73. PubMed ID: 36758322
[TBL] [Abstract][Full Text] [Related]
19. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA; Aminawung JA; Abu-Khalaf MM; Evans SB; Su K; Mehta R; Wang SY; Gross CP
J Natl Compr Canc Netw; 2017 Mar; 15(3):346-354. PubMed ID: 28275035
[No Abstract] [Full Text] [Related]
20. Conveying genomic recurrence risk estimates to patients with early-stage breast cancer: oncologist perspectives.
Spellman E; Sulayman N; Eggly S; Peshkin BN; Isaacs C; Schwartz MD; O'Neill SC
Psychooncology; 2013 Sep; 22(9):2110-6. PubMed ID: 23447452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]